_ok_o_ff.png)
1.png)
Clinical Outcomes of Antihypertensive Therapy in Chronic Kidney Disease: A Literature Review
Abstract
Keywords
Full Text:
PDFReferences
Deng L, Guo S, Liu Y, Zhou Y, Liu Y, Zheng X, et al. Global, regional, and national burden of chronic kidney disease and its underlying etiologies from 1990 to 2021: a systematic analysis for the Global Burden of Disease Study 2021. BMC Public Health [Internet]. 2025 Feb 17; 25(1). Available from: https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-025-21851-z
Cheung AK, Chang TI, Cushman WC, Furth SL, Hou FF, Ix JH, et al. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney International [Internet]. 2021 Mar; 99(3):S1–87. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0085253820312709
Ku E, Lee BJ, Wei J, Weir MR. Hypertension in CKD: Core Curriculum 2019. American Journal of Kidney Diseases [Internet]. 2019 Jul [cited 2025 Jul 9];74(1):120–31. Available: https://linkinghub.elsevier.com/retrieve/pii/S0272638619300940
Zhang Y, He D, Zhang W, Xing Y, Guo Y, Wang F, et al. ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3–5: A Network Meta-Analysis of Randomised Clinical Trials. Drugs [Internet]. 2020 Jun; 80(8):797–811. Available: https://link.springer.com/10.1007/s40265-020-01290-3
Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. 2020;
Huang RS, Cheng YM, Zeng XX, Kim S, Fu P. Renoprotective Effect of the Combination of Renin-angiotensin System Inhibitor and Calcium Channel Blocker in Patients with Hypertension and Chronic Kidney Disease. Chinese Medical Journal [Internet]. 2016 Mar 5; 129(5):562–9. Available: https://journals.lww.com/00029330-201603050-00010
Takayama T, Yoda S, Yajima Y, Kasamaki Y, Kunimoto S, Kanai T, et al. Improvements in Augmentation Index and Urinary Albumin Excretion With Benidipine in Hypertensive Patients With Chronic Kidney Disease. Int Heart J [Internet]. 2016 ;57(1):53–60. Available: https://www.jstage.jst.go.jp/article/ihj/57/1/57_15-208/_article
Mancia G, Cha G, Gil-Extremera B, Harvey P, Lewin AJ, Villa G, et al. Blood pressure-lowering effects of nifedipine/candesartan combinations in high-risk individuals: subgroup analysis of the DISTINCT randomised trial. J Hum Hypertens [Internet]. 2017 Mar; 31(3):178–88. Available: https://www.nature.com/articles/jhh201654
Burnier M, Damianaki A. Hypertension as Cardiovascular Risk Factor in Chronic Kidney Disease. Circulation Research [Internet]. 2023 Apr 14; 132(8):1050–63. Available: https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.122.321762
Indriani GN, Hajrah, Ahmad I. Evaluation of Antihypertensive Drug Use in Chronic Kidney Failure Patients on Hemodialysis at RSUD A.M. Parikesit Tenggarong: Evaluasi Penggunaan Obat Antihipertensi pada Pasien Gagal Ginjal Kronis dengan Hemodialisis di RSUD A.M. Parikesit Tenggarong. J Riseta Naturafarm [Internet]. 2025 Mar 10; 2(1):21–32. Available: https://jrn.b-creta.com/index.php/jrn/article/view/13
McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. European Heart Journal [Internet]. 2024 Oct 7; 45(38):3912–4018. Available: https://academic.oup.com/eurheartj/article/45/38/3912/7741010
Jones DW, Ferdinand KC, Taler SJ, Johnson HM, Shimbo D, Abdalla M, et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation [Internet]. 2025 Sep 16; 152(11). Available: https://www.ahajournals.org/doi/10.1161/CIR.0000000000001356
World Health Organization (WHO), Guideline for the Pharmacological Treatment of Hypertension in Adults, 1st ed. Geneva: World Health Organization, 2021. [Online]. Available: https://www.who.int/publications/i/item/9789240033986
Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). Journal of Hypertension [Internet]. 2023 Dec; 41(12):1874–2071. Available: https://journals.lww.com/10.1097/HJH.0000000000003480
Stevens PE, Ahmed SB, Carrero JJ, Foster B, Francis A, Hall RK, et al. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International [Internet]. 2024 Apr; 105(4):S117–314. Available: https://linkinghub.elsevier.com/retrieve/pii/S0085253823007664
Sinha AD, Agarwal R. Clinical Pharmacology of Antihypertensive Therapy for the Treatment of Hypertension in CKD. CJASN [Internet]. 2019 May; 14(5):757–64. Available from: https://journals.lww.com/01277230-201905000-00020
Susantitaphong P, Sewaralthahab K, Balk EM, Eiam-ong S, Madias NE, Jaber BL. Efficacy and Safety of Combined vs. Single Renin-Angiotensin-Aldosterone System Blockade in Chronic Kidney Disease: A Meta-Analysis. American Journal of Hypertension [Internet]. 2013 Mar 1 [cited 2025 Jul 17];26(3):424–41. Available: https://academic.oup.com/ajh/article-lookup/doi/10.1093/ajh/hps038
Bhandari S, Mehta S, Khwaja A, Cleland JGF, Ives N, Brettell E, et al. Renin–Angiotensin System Inhibition in Advanced Chronic Kidney Disease. N Engl J Med [Internet]. 2022 Dec ;387(22):2021–32. Available: http://www.nejm.org/doi/10.1056/NEJMoa2210639
Suehiro T, Tsuruya K, Yoshida H, Tsujikawa H, Yamada S, Tanaka S, et al. Stronger Effect of Azilsartan on Reduction of Proteinuria Compared to Candesartan in Patients with CKD: A Randomized Crossover Trial. Kidney Blood Press Res [Internet]. 2021 ;46(2):173–84. Available: https://karger.com/article/doi/10.1159/000512365
Gant CM, Laverman GD, Vogt L, Slagman MCJ, Heerspink HJL, Waanders F, et al. Renoprotective RAAS inhibition does not affect the association between worse renal function and higher plasma aldosterone levels. BMC Nephrol [Internet]. 2017 Dec;18(1):370. Available: https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-017-0789-x
Mårup FH, Peters CD, Christensen JH, Birn H. Can patiromer allow for intensified renin–angiotensin–aldosterone system blockade with losartan and spironolactone leading to decreased albuminuria in patients with chronic kidney disease, albuminuria and hyperkalaemia? An open-label randomised controlled trial: MorphCKD. BMJ Open [Internet]. 2022 Feb;12(2):e057503. Available: https://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2021-057503
Zhao HJ, Li Y, Liu SM, Sun XG, Li M, Hao Y, et al. Effect of calcium channels blockers and inhibitors of the renin-angiotensin system on renal outcomes and mortality in patients suffering from chronic kidney disease: systematic review and meta-analysis. Renal Failure [Internet]. 2016 Jul 2; 38(6):849–56. Available: http://www.tandfonline.com/doi/full/10.3109/0886022X.2016.1165065
Zhao M, Zhang Z, Pan Z, Ma S, Chang M, Fan J, et al. N-/T-Type vs. L-Type Calcium Channel Blocker in Treating Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Pharmaceuticals [Internet]. 2023 Feb 22; 16(3):338. Available: https://www.mdpi.com/1424-8247/16/3/338
DOI: https://doi.org/10.37311/jsscr.v7i3.34331
Refbacks
- There are currently no refbacks.
Copyright (c) 2025 Journal Syifa Sciences and Clinical Research
| EDITORIAL OFFICE OF JOURNAL SYIFA SCIENCES AND CLINICAL RESEARCH |
| Department of Pharmacy, Gorontalo State University Jl. Jenderal Sudirman No.6, Kota Gorontalo, Provinsi Gorontalo 96128, Indonesia |
| Email: [email protected] Google Scholar : JOURNAL SYIFA SCIENCES AND CLINICAL RESEARCH |
